On the other hand, the present data suggest that cancer cells in the patient cohort with low levels of UCP2 and PRMT1 might be metabolically less active, yielding attenuated cancer cell proliferation and, thus, increased patient survival. The gene discussed is PRMT1; the disease is cancer.